Happy to see this come thru!

Join me in the UCI Anti-Cancer Challenge by donating here: anti-cancerchallenge.org/MISAKONAGASAKA

So excited to join this amazing session ✨

Is the addition of adjuvant IO beneficial post neoadjuvant chemo-IO? If so, when and how much? Great presentation by Dr Heymach. #AACR

With my amazing scientist partner ASFAR AZMI

Upcoming #virtual Advances in Cancer Immunotherapy™: A Focus on Lung Cancers on April 6, featuring authorities in cancer immunotherapy. Free for healthcare professionals in a clinical setting. Register now: sitcancer.org/education/aci/…
#LearnACI
Misako Nagasaka Sandip Patel MD

Host Misako Nagasaka from UC Irvine, leads a Japanese-language discussion about #lungcancer in Japan with respected oncologists Tetsuya Mitsudomi, (past IASLC president) from Kindai University, and Takashi Seto MD, from the National Kyushu Cancer Center. Listen Now: bit.ly/3CQ4MJ3 #LCSM

ESMO2022. Excellent talk by Dr Spicer on neoadjuvant chemo-IO + surgery! Yes, seeing is believing. I’ve also seen a few pCR, too. Just wish we’d know beforehand who they r.

Finally!! Another excellent drug for patients with NSCLC. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer fda.gov/drugs/resource…

A quick editorial with my amazing friend and collaborator 😊

Congratulations to ASFAR AZMI and the team

Happy to join a great discussion!

Happy to b part of this exciting effort. biorxiv.org/content/10.110…
 ASFAR AZMI

Today is #GivingTuesday ! Donate to our campaign to conquer lung cancer worldwide! Your donation funds grant recipients like Dr. Tejas Patil. He says, “Donations to ILCF are critical towards supporting novel ideas that could directly impact patients.” donorbox.org/iaslc-donate-g…

Our new review is now online. Such a fast paced field it’s hard to keep up. Bindu Potugari Sai-Hong Ignatius Ou ASFAR AZMI

Great job, especially Ibrahim Azar, MD and Samer Alkassis, MD !!

Congratulations to the team !!
Thank you for posting Stephen. Vijendra Singh Chul Kim Hirva Mamdani Alex Spira, M.D. @dipeshuprety4 Edward S. Kim, MD, MBA, FACP, FASCO Luis E Raez Matthew Oberley Rebecca Feldman, PhD @Joanne_XXA W. Michael Korn Hossein Borghaei, DO Stephen V Liu, MD

My first NEJM paper. Trastuzumab deruxtecan in HER2 mutant lung. Confirmed RR 55%, mPFS 8.2 and mOS 17.8 months in previously treated patients.
Big thank you to our patients and families and our clinical trial team. Congratulations to my co-authors!

nejm.org/doi/full/10.10…

Sharing our work on XPO1 and NSCLC. Congrats to the team. ASFAR AZMI M Fahad B Asad Najeeb Al Hallak @Joanne_XXA Hirva Mamdani @dipeshuprety4 Chul Kim Stephen V Liu, MD Jorge Nieva gilberto lopes Hossein Borghaei, DO Luis E Raez Patrick C. Ma, MD Sonam Puri MD W. Michael Korn

Absolutely! Will discuss and offer when approved. For patients, DFS may be enough to go on atezo.